India's BDR Pharma seeks licence to sell version of Bristol-Myers Squibb cancer drug
MUMBAI, March 18
MUMBAI, March 18 (Reuters) - India's BDR Pharmaceuticals International Pvt Ltd has applied to the Indian patents office, seeking permission to sell a generic version of Bristol-Myers Squibb Co's cancer drug, dasatinib, through a so-called compulsory licence mechanism, a BDR executive said on Monday.
Under a global Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, countries can issue compulsory licences for certain drugs that are deemed unaffordable to a large section of their populations.
Early this month, Bayer AG lost an appeal challenging the first-ever compulsory licence issued by India which allowed Natco Pharma to sell a version of the German drugmaker's cancer treatment Nexavar.
- Ferguson protest march marks two weeks since police shooting |
- Gaza gunmen execute 'collaborators'; mortar kills Israeli boy |
- Merkel says tightening Ukraine-Russian border is key to peace deal |
- U.S. says Russia must pull convoy from Ukraine or face more sanctions |
- U.S. hostage rescuers dropped from night sky: Syria activist